Indomethacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Indomethacin: From an Established NSAID to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Indomethacin is a marketed non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, but there are 0 clinical trials and 0 publications for this indication. The prediction rests on the model score alone and no plausible mechanistic link has been identified.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Based on general pharmacology, indomethacin is a non-selective COX-1/COX-2 inhibitor that reduces prostaglandin synthesis. That makes it useful for inflammation, pain, and fever.
Brachydactyly-syndactyly syndrome is a congenital limb malformation with a genetic and developmental basis. There is no known inflammatory driver that COX inhibition would address. The high score (0.9997) most likely reflects graph proximity in the knowledge graph, not a biological rationale.
Overall, this prediction is not mechanistically supported, and the evidence is model output only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Five of the 20 authorizations are listed below. The source data does not include approved indication text for these products.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA091240 | Indomethacin | Capsule | Bryant Ranch Prepack |
| ANDA091240 | Indomethacin | Capsule | XLCare Pharmaceuticals Inc. |
| ANDA201807 | Indomethacin | Capsule, extended release | Proficient Rx LP |
| ANDA073314 | INDOCIN | Suppository | Zyla Life Sciences US Inc. |
| ANDA091276 | INDOMETHACIN | Capsule | DIRECT RX |
Available routes are oral (capsule, extended-release capsule) and other (suppository).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5 prediction with no trials, no literature, and no plausible mechanism. Congenital limb malformation is not expected to respond to COX inhibition.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any mechanistic or preclinical evidence linking prostaglandin pathways to this syndrome
Note on other predictions: Among the top 10 predictions, only juvenile idiopathic arthritis (rank 8, L3) has meaningful literature support. That support is mostly old NSAID literature, including a 1978 double-blind trial comparing ketoprofen and indomethacin in children, and it points to symptomatic relief rather than disease modification. It is better evaluated as a separate research question against current JIA guidelines and pediatric safety data (GI, renal, and bleeding risks).
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.